Rosetta
Genomics Ltd. ROSG, a leading developer and provider of
microRNA-based molecular diagnostics, announces that the Company has executed
a credentialing agreement with Prime Health Services, Inc. (Prime Health), a
managed care company that offers a full spectrum of services, including a
Preferred Provider Organization (PPO), for the inclusion of Rosetta Genomics'
miRview^® mets^2 test in Prime Health's covered products and services.
The agreement with Prime Health is the first credentialing agreement executed
between Rosetta Genomics and a U.S. PPO, and increases the number of covered
lives for which its miRview^® mets^2 test could be adjudicated as "in-network"
to more than 6.5 million.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in